New lung drug LYT-100 aims to slow IPF progression
Disease control
Ongoing
This study tests a new drug called LYT-100 in 240 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing harder. The goal is to see if LYT-100 can slow the decline in lung function better than an existing drug (pirfenidone…
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated May 15, 2026 11:55 UTC